This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
braf
BRAF
Serine/threonine kinase; V600E mutation constitutively activates MEK-ERK without RAS input. Mutated in ~50% of melanomas, 60% of papillary thyroid cancers, and 10% of CRC. Combined BRAF+MEK inhibition (dabrafenib+trametinib) is standard of care in V600E-mutant melanoma.
Entry Metadata
| Field | Value |
|---|---|
| ID | braf |
| Name | BRAF |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. · PubMed 12068308
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516. · PubMed 21639808
- Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39. · PubMed 25399551